ReShape Lifesciences (RSLS) SC 13G Obalon Therapeutics Inc

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

_____________________

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

TO RULES 13d-1(b),(c) AND (d) AND AMENDMENTS THERETO FILED

PURSUANT TO RULE 13d-2(b)

(Amendment No.  )¹

Obalon Therapeutics, Inc.

(Name of Issuer)

Common Stock, $0.001 par value

(Title of Class of Securities)

67424L100

(CUSIP Number)

December 31, 2016

Date of Event Which Requires Filing of this Statement

Check the appropriate box to designate the rule pursuant to which this Schedule is Filed:

[   ] Rule 13d-1(b)

[   ] Rule 13d-1(c)

[X] Rule 13d-1(d)

_______________________

¹The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.  The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

CUSIP No. 67424L100

1)	Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) (Voluntary)	Domain Partners VII, L.P.
2)	Check the Appropriate Box if a Member of a Group	(a)  [X] (b)  [   ]
3)	SEC Use Only
4)	Citizenship or Place of Organization	Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5)	Sole Voting Power	4,005,819 shares of Common Stock *
		6)	Shared Voting Power	-0-
		7)	Sole Dispositive Power	4,005,819 shares of Common Stock *
		8)	Shared Dispositive Power	-0-
9)	Aggregate Amount Beneficially Owned by Each Reporting Person	4,005,819 shares of Common Stock *
10)	Check if the Aggregate Amount in Row (9) Excludes Certain Shares	[   ]
11)	Percent of Class Represented by Amount in Row (9)	23.9% **
12)	Type of Reporting Person	PN

* As of December 31, 2016 and including 19,849 shares issuable upon exercise of warrants to purchase Common Stock.

** Based on 16,773,205 shares of Common Stock outstanding as of December 31, 2016, as provided to the Reporting Persons by the Issuer.

2

CUSIP No. 67424L100

1)	Name of Reporting Person I.R.S. Identification No. of Above Person (Entities Only) (Voluntary)	DP VII Associates, L.P.
2)	Check the Appropriate Box if a Member of a Group	(a)  [X] (b)  [   ]
3)	SEC Use Only
4)	Citizenship or Place of Organization	Delaware
Number of Shares Beneficially Owned by Each Reporting Person With		5)	Sole Voting Power	49,908 shares of Common Stock *
		6)	Shared Voting Power	-0-
		7)	Sole Dispositive Power	49,908 shares of Common Stock *
		8)	Shared Dispositive Power	-0-
9)	Aggregate Amount Beneficially Owned by Each Reporting Person	49,908 shares of Common Stock *
10)	Check if the Aggregate Amount in Row (9) Excludes Certain Shares	[   ]
11)	Percent of Class Represented by Amount in Row (9)	0.3% **
12)	Type of Reporting Person	PN

* As of December 31, 2016 and including 338 shares issuable upon exercise of warrants to purchase Common Stock.

** Based on 16,773,205 shares of Common Stock outstanding as of December 31, 2016, as provided to the Reporting Persons by the Issuer.

3

CUSIP No. 67424L100

Schedule 13G

Item 1(a)	–	Name of Issuer:
		Obalon Therapeutics, Inc.
Item 1(b)	–	Address of Issuer's Principal Executive Offices:
		5421 Avenida Encinas, Suite F, Carlsbad, CA  92008
Item 2(a)	–	Name of Person Filing:
		This statement is being filed by Domain Partners VII, L.P., a Delaware limited partnership ("Domain VII"), and DP VII Associates, L.P., a Delaware limited partnership ("DP VII A") (together, the "Reporting Persons").
Item 2(b)	–	Address of Principal Business Office:
		One Palmer Square, Princeton, NJ  08542
Item 2(c)	–	Place of Organization:
		Domain VII:  Delaware
		DP VII A:  Delaware
Item 2(d)	–	Title of Class of Securities:
		Common Stock, $0.001 par value
Item 2(e)	–	CUSIP Number:
		67424L100
Item 3	–	Statements Filed Pursuant to Rules 13d-1(b) or 13d-2(b):
		Not applicable.

4

CUSIP No. 67424L100
 

Item 4	–	Ownership.
(a) through (c):
The information set forth in Items 5 through 9 and 11 of the cover pages to this Schedule 13G is incorporated herein by reference.
Item 5	–	Ownership of Five Percent or Less of a Class:
		Not applicable.
Item 6	–	Ownership of More than Five Percent on Behalf of Another Person:
		Not applicable.
Item 7	–	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Company:
		Not applicable.
Item 8	–	Identification and Classification of Members of the Group:
		See Exhibit 2.
Item 9	–	Notice of Dissolution of Group:
		Not applicable.
Item 10	–	Certification:
		Not applicable.

5

CUSIP No. 67424L100

Signature

After reasonable inquiry and to the best of their knowledge and belief, the undersigned hereby certify that the information set forth in this statement is true, complete and correct.

Dated:  January 9, 2017

DOMAIN PARTNERS VII, L.P.
By:	One Palmer Square Associates VII, L.L.C., General Partner
By:	/s/ Lisa A. Kraeutler
	Attorney-in-Fact
DP VII ASSOCIATES, L.P.
By:	One Palmer Square Associates VII, L.L.C., General Partner
By:	/s/ Lisa A. Kraeutler
	Attorney-in-Fact

6

CUSIP No. 67424L100

Exhibit 1

Joint Filing Agreement

The undersigned hereby agree that the statement on Schedule 13G to which this Agreement is annexed as Exhibit 1, and any amendments thereto, is and will be filed on behalf of each of them in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

Dated:  January 9, 2017

DOMAIN PARTNERS VII, L.P.
By:	One Palmer Square Associates VII, L.L.C., General Partner
By:	/s/ Lisa A. Kraeutler
	Attorney-in-Fact
DP VII ASSOCIATES, L.P.
By:	One Palmer Square Associates VII, L.L.C., General Partner
By:	/s/ Lisa A. Kraeutler
	Attorney-in-Fact

7

CUSIP No. 67424L100

Exhibit 2

Identification and Classification of Members of the Group

Domain Partners VII, L.P. and DP VII Associates, L.P. are filing this statement on Schedule 13G as a group.

Domain Partners VII, L.P. is a Delaware limited partnership.  Its sole general partner is One Palmer Square Associates VII, L.L.C., a Delaware limited liability company.

DP VII Associates, L.P. is a Delaware limited partnership.  Its sole general partner is One Palmer Square Associates VII, L.L.C., a Delaware limited liability company.

8